Hydroxycarbamid Eugia

Hydroxycarbamide, the active ingredient in Hydroxycarbamid Eugia, is an antimetabolite presented as an oral tablet for systemic administration. It is used to manage specific hematologic malignancies and blood disorders, including chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and sickle cell disease, primarily in adult patients and may be prescribed by hematologists as part of a disease‑modifying regimen.

GNH USA supplies Hydroxycarbamid Eugia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide with reliable logistics and regulatory support.

Hydroxycarbamide is an antimetabolite used in the treatment of myeloproliferative disorders and sickle cell disease.

Chronic myelogenous leukemia: reduces leukemic cell proliferation and improves hematologic control. Polycythemia vera: lowers red blood cell mass and decreases risk of thrombosis. Essential thrombocythemia: normalizes platelet counts and reduces thrombotic complications. Sickle cell disease: increases fetal hemoglobin production, decreasing vaso‑occlusive crises.

Hydroxycarbamid Eugia may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Hair thinning: temporary loss of scalp hair. - Skin discoloration: hyperpigmentation of the skin or nails. - Mouth ulcers: painful sores in the oral cavity.

Serious or Rare Side Effects: - Bone marrow suppression: severe anemia, leukopenia, or thrombocytopenia requiring monitoring. - Renal toxicity: impaired kidney function manifested by increased creatinine. - Cutaneous ulcers: non‑healing skin lesions, especially on the lower extremities.

Hydroxycarbamid Eugia requires careful monitoring and specific safety measures. - Dose adjustment: modify dose based on complete blood count results. - Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk. - Breastfeeding: avoid use while nursing because drug is excreted in milk. - Renal impairment: assess kidney function before initiating therapy. - Monitoring: perform regular CBC, liver and renal tests during treatment. - Store at ambient temperature: keep below 25°C, retain in original container, protect from moisture and light.

Hydroxycarbamid Eugia can interact with several medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid): - Live vaccines: concurrent use may increase risk of infection. - Antiretroviral protease inhibitors: may increase hydroxycarbamide plasma levels. - Azathioprine: additive bone marrow suppression.

Moderate Interactions (Monitor Closely): - Allopurinol: may enhance toxicity, monitor blood counts. - Phenytoin: may reduce hydroxycarbamide efficacy, adjust dose if needed. - NSAIDs: may increase risk of renal dysfunction, monitor renal function.